Work

Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report

Year: 2025

Type: article

Abstract: BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) represents a distinct molecular cancer subtype that is often associated with a poor prognosis. While perioperative chemotherapy regimens are currently the primary recommendation for locally advanced HER2-positive GC, combination therapies incorporating immune checkpoint inhibitors are under active investigation. CASE SUMMARY: The present case describes a patient with locally advanced HER2-positive GC who underwent perioperative treatment with chemotherapy combined with trastuzumab. Although significant tumor shrinkage was observed, surgical pathology results did not confirm the achievement of a pathological complete response. The current treatment strategies for advanced GC were also reviewed. Relevant case reports, retrospective studies, and prospective clinical trials were retrieved for analysis after searching the PubMed/MEDLINE, EMBASE, Cochrane Library, Web of Science, and American Society of Clinical Oncology/European Society for Medical Oncology conference abstracts between 2014 and 2024. CONCLUSION: Large-scale phase III clinical trials are needed to verify the efficacy of combined neoadjuvant treatment application for GC.

Source: World Journal of Clinical Oncology

DOI: 10.5306/wjco.v16.i11.112029

Authors: Xiao-Ting Ma, Guang-Yu Yao, Jian-Li Li, Xi-Cheng Wang, Yi Ba

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Affiliated Hospital of Changzhi Institute of Traditional Chinese Medicine

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: F. Hoffmann-La Roche, Genentech